RESUMEN

BACKGROUND: Epilepsy, a chronic brain disorder characterized by abnormal brain activity that causes seizures and other symptoms, is typically treated using anti-epileptic drugs (AEDs) as the first-line therapy. However, due to the variations in their modes of action, identification of effective AEDs often relies on ad hoc trials, which is particularly challenging for pediatric patients. Thus, there is significant value in computational methods capable of assisting in the selection of AEDs, aiming to minimize unnecessary medication and improve treatment efficacy. RESULTS: In this study, we collected 7,507 medical records from 1,000 pediatric epilepsy patients and developed a computational clinical decision-supporting system for AED selection. This system leverages three multi-channel convolutional neural network (CNN) models tailored to three specific AEDs (vigabatrin, prednisolone, and clobazam). Each CNN model predicts whether a respective AED is effective on a given patient or not. The CNN models showed AUROCs of 0.90, 0.80, and 0.92 in 10-fold cross-validation, respectively. Evaluation on a hold-out test dataset further revealed positive predictive values (PPVs) of 0.92, 0.97, and 0.91 for the three respective CNN models, representing that suggested AEDs by our models would be effective in controlling epilepsy with a high accuracy and thereby reducing unnecessary medications for pediatric patients. CONCLUSION: Our CNN models in the system demonstrated high PPVs for the three AEDs, which signifies the potential of our approach to support the clinical decision-making by assisting doctors in recommending effective AEDs within the three AEDs for patients based on their medical history. This would result in a reduction in the number of unnecessary ad hoc attempts to find an effective AED for pediatric epilepsy patients.

Asunto(s)

RESUMEN

OBJECTIVES: The potential of artificial intelligence (AI) chatbots, particularly the fourth-generation chat generative pretrained transformer (ChatGPT-4), in assisting with medical diagnosis is an emerging research area. While there has been significant emphasis on creating lists of differential diagnoses, it is not yet clear how well AI chatbots can evaluate whether the final diagnosis is included in these lists. This short communication aimed to assess the accuracy of ChatGPT-4 in evaluating lists of differential diagnosis compared to medical professionals' assessments. METHODS: We used ChatGPT-4 to evaluate whether the final diagnosis was included in the top 10 differential diagnosis lists created by physicians, ChatGPT-3, and ChatGPT-4, using clinical vignettes. Eighty-two clinical vignettes were used, comprising 52 complex case reports published by the authors from the department and 30 mock cases of common diseases created by physicians from the same department. We compared the agreement between ChatGPT-4 and the physicians on whether the final diagnosis was included in the top 10 differential diagnosis lists using the kappa coefficient. RESULTS: Three sets of differential diagnoses were evaluated for each of the 82 cases, resulting in a total of 246 lists. The agreement rate between ChatGPT-4 and physicians was 236 out of 246 (95.9 %), with a kappa coefficient of 0.86, indicating very good agreement. CONCLUSIONS: ChatGPT-4 demonstrated very good agreement with physicians in evaluating whether the final diagnosis should be included in the differential diagnosis lists.

Asunto(s)

RESUMEN

BACKGROUND: In this study, we evaluated the diagnostic accuracy of Google Bard, a generative artificial intelligence (AI) platform. METHODS: We searched published case reports from our department for difficult or uncommon case descriptions and mock cases created by physicians for common case descriptions. We entered the case descriptions into the prompt of Google Bard to generate the top 10 differential-diagnosis lists. As in previous studies, other physicians created differential-diagnosis lists by reading the same clinical descriptions. RESULTS: A total of 82 clinical descriptions (52 case reports and 30 mock cases) were used. The accuracy rates of physicians were still higher than Google Bard in the top 10 (56.1% vs 82.9%, P < .001), the top 5 (53.7% vs 78.0%, P = .002), and the top differential diagnosis (40.2% vs 64.6%, P = .003). Even within the specific context of case reports, physicians consistently outperformed Google Bard. When it came to mock cases, the performances of the differential-diagnosis lists by Google Bard were no different from those of the physicians in the top 10 (80.0% vs 96.6%, P = .11) and the top 5 (76.7% vs 96.6%, P = .06), except for those in the top diagnoses (60.0% vs 90.0%, P = .02). CONCLUSION: While physicians excelled overall, and particularly with case reports, Google Bard displayed comparable diagnostic performance in common cases. This suggested that Google Bard possesses room for further improvement and refinement in its diagnostic capabilities. Generative AIs, including Google Bard, are anticipated to become increasingly beneficial in augmenting diagnostic accuracy.

RESUMEN

Model informed precision dosing for warfarin is to provide individualized dosing by integrating information related to patient characteristics, disease status and pharmacokinetics /pharmacodynamics of warfarin, through mathematical modeling and simulation techniques based on the quantitative pharmacology. Compared with empirical dosing, it can improve the safety, effectiveness, economy, and adherence of pharmacotherapy of warfarin. This consensus report describes the commonly used modeling and simulation techniques for warfarin, their application in developing and adjusting dosing regimens, medication adherence and economy. Moreover, this consensus also elaborates the detailed procedures for the implementation in the warfarin pharmacy service pathway to facilitate the development and application of model informed precision dosing for warfarin.

RESUMEN

Model informed precision dosing (MIPD) is a new concept to guide precision dosing for individual patient by modeling and simulation based on the available information about the individual patient, medications and the disease. Compared to the empirical dosing, MIPD could improve the efficacy, safety, economics and adherence of the pharmacotherapy according to the individual's pathophysiology, genotyping and disease progression. This consensus report provides a brief account of the concept, methodology and implementation of MIPD as well as clinical decision supporting systems for MIPD. The status and future advancing of MIPD was also discussed to facilitate the appropriate application and development of MIPD in China.

RESUMEN

Reliable data support, information technology and its products are needed to achieve the target of big data-based precision medicine.The mature clinical decision supporting products , such as seamless information product and nursing decision supporting products (my cancer genome and Watson) and studies on their related evi-dence in foreign countries were thus described in this paper with suggestions put forward for scientific achievements in genomes and in docking and integrating clinical electronic medical records, such as training learned bioinformatics professionals, sharing medical data, working out need-guided research strategies, constructing basic bioinformatics framework and cancer knowledge network.